APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pet Biopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pet Biopharmaceuticals Market Outlook and Growth Opportunities 2026

Report ID 174024070430 December 2025196 pages

Choose your research edition.

Industry ResearchPet Biopharmaceuticals Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Pet Biopharmaceuticals Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Pet Biopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pet Biopharmaceuticals Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Pet Biopharmaceuticals Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Pet Biopharmaceuticals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pet Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pet Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pet Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pet Biopharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pet Biopharmaceuticals market include Merck, Zoetis, Virbac, Vetoquinol, Ouro Fino Saude, Norbrook, Jindun, Elanco and Dechra Veterinary Products, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Pet Biopharmaceuticals market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pet Biopharmaceuticals and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pet Biopharmaceuticals revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pet Biopharmaceuticals market.

Pet Biopharmaceuticals Segment by Company

Merck

Zoetis

Virbac

Vetoquinol

Ouro Fino Saude

Norbrook

Jindun

Elanco

Dechra Veterinary Products

Chopperlvya Animal Health

Ceva

CAHIC

Boehringer Ingelheim

Pet Biopharmaceuticals Segment by Type

Antiparasitic

Antibacterial

Biological Products

Others

Pet Biopharmaceuticals Segment by Application

Prevention

Treatment

Pet Biopharmaceuticals Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Pet Biopharmaceuticals status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pet Biopharmaceuticals key companies, revenue, market share, and recent developments.

3. To split the Pet Biopharmaceuticals breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pet Biopharmaceuticals market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pet Biopharmaceuticals significant trends, drivers, influence factors in global and regions.

6. To analyze Pet Biopharmaceuticals competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pet Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pet Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pet Biopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pet Biopharmaceuticals industry.

Chapter 3: Detailed analysis of Pet Biopharmaceuticals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pet Biopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pet Biopharmaceuticals in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pet Biopharmaceuticals Industry Trends Table 2. Pet Biopharmaceuticals Industry Drivers Table 3. Pet Biopharmaceuticals Industry Opportunities and Challenges Table 4. Pet Biopharmaceuticals Industry Restraints Table 5. Global Pet Biopharmaceuticals Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pet Biopharmaceuticals Revenue Share by Company (2021-2026) Table 7. Global Pet Biopharmaceuticals Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pet Biopharmaceuticals Key Company Manufacturing Base & Headquarters Table 9. Global Pet Biopharmaceuticals Company, Product Type & Application Table 10. Global Pet Biopharmaceuticals Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pet Biopharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Antiparasitic Table 15. Significant Companies of Antibacterial Table 16. Significant Companies of Biological Products Table 17. Significant Companies of Others Table 18. Global Pet Biopharmaceuticals Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Pet Biopharmaceuticals Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Pet Biopharmaceuticals Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Pet Biopharmaceuticals Sales Value Share by Type (2021-2026) Table 22. Global Pet Biopharmaceuticals Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Prevention Table 24. Significant Companies of Treatment Table 25. Global Pet Biopharmaceuticals Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Pet Biopharmaceuticals Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Pet Biopharmaceuticals Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Pet Biopharmaceuticals Sales Value Share by Application (2021-2026) Table 29. Global Pet Biopharmaceuticals Sales Value Share by Application (2027-2032) Table 30. Global Pet Biopharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Pet Biopharmaceuticals Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Pet Biopharmaceuticals Sales Value Share by Region (2021-2026) Table 33. Global Pet Biopharmaceuticals Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Pet Biopharmaceuticals Sales Value Share by Region (2027-2032) Table 35. Global Pet Biopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Pet Biopharmaceuticals Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Pet Biopharmaceuticals Sales Value Market Share by Country (2021-2026) Table 38. Global Pet Biopharmaceuticals Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Pet Biopharmaceuticals Sales Value Market Share by Country (2027-2032) Table 40. Merck Company Information Table 41. Merck Business Overview Table 42. Merck Pet Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Merck Pet Biopharmaceuticals Product Portfolio Table 44. Merck Recent Development Table 45. Zoetis Company Information Table 46. Zoetis Business Overview Table 47. Zoetis Pet Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Zoetis Pet Biopharmaceuticals Product Portfolio Table 49. Zoetis Recent Development Table 50. Virbac Company Information Table 51. Virbac Business Overview Table 52. Virbac Pet Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Virbac Pet Biopharmaceuticals Product Portfolio Table 54. Virbac Recent Development Table 55. Vetoquinol Company Information Table 56. Vetoquinol Business Overview Table 57. Vetoquinol Pet Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Vetoquinol Pet Biopharmaceuticals Product Portfolio Table 59. Vetoquinol Recent Development Table 60. Ouro Fino Saude Company Information Table 61. Ouro Fino Saude Business Overview Table 62. Ouro Fino Saude Pet Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Ouro Fino Saude Pet Biopharmaceuticals Product Portfolio Table 64. Ouro Fino Saude Recent Development Table 65. Norbrook Company Information Table 66. Norbrook Business Overview Table 67. Norbrook Pet Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Norbrook Pet Biopharmaceuticals Product Portfolio Table 69. Norbrook Recent Development Table 70. Jindun Company Information Table 71. Jindun Business Overview Table 72. Jindun Pet Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Jindun Pet Biopharmaceuticals Product Portfolio Table 74. Jindun Recent Development Table 75. Elanco Company Information Table 76. Elanco Business Overview Table 77. Elanco Pet Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Elanco Pet Biopharmaceuticals Product Portfolio Table 79. Elanco Recent Development Table 80. Dechra Veterinary Products Company Information Table 81. Dechra Veterinary Products Business Overview Table 82. Dechra Veterinary Products Pet Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Dechra Veterinary Products Pet Biopharmaceuticals Product Portfolio Table 84. Dechra Veterinary Products Recent Development Table 85. Chopperlvya Animal Health Company Information Table 86. Chopperlvya Animal Health Business Overview Table 87. Chopperlvya Animal Health Pet Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Chopperlvya Animal Health Pet Biopharmaceuticals Product Portfolio Table 89. Chopperlvya Animal Health Recent Development Table 90. Ceva Company Information Table 91. Ceva Business Overview Table 92. Ceva Pet Biopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Ceva Pet Biopharmaceuticals Product Portfolio Table 94. Ceva Recent Development Table 95. CAHIC Company Information Table 96. CAHIC Business Overview Table 97. CAHIC Pet Biopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. CAHIC Pet Biopharmaceuticals Product Portfolio Table 99. CAHIC Recent Development Table 100. Boehringer Ingelheim Company Information Table 101. Boehringer Ingelheim Business Overview Table 102. Boehringer Ingelheim Pet Biopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Boehringer Ingelheim Pet Biopharmaceuticals Product Portfolio Table 104. Boehringer Ingelheim Recent Development Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Pet Biopharmaceuticals Product Image Figure 2. Global Pet Biopharmaceuticals Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pet Biopharmaceuticals Market Size (2021-2032) & (US$ Million) Figure 4. Global Pet Biopharmaceuticals Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Antiparasitic Image Figure 8. Antibacterial Image Figure 9. Biological Products Image Figure 10. Others Image Figure 11. Global Pet Biopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Pet Biopharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Pet Biopharmaceuticals Sales Value Share by Type (2021-2032) Figure 14. Prevention Image Figure 15. Treatment Image Figure 16. Global Pet Biopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Pet Biopharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Pet Biopharmaceuticals Sales Value Share by Application (2021-2032) Figure 19. Global Pet Biopharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Pet Biopharmaceuticals Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Pet Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 22. North America Pet Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Pet Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Pet Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Pet Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Pet Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Pet Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 28. South America Pet Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Pet Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Pet Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Antiparasitic
  • Antibacterial
  • Biological Products
  • Others
Applications
  • Prevention
  • Treatment
Companies covered
  • Merck
  • Zoetis
  • Virbac
  • Vetoquinol
  • Ouro Fino Saude
  • Norbrook
  • Jindun
  • Elanco
  • Dechra Veterinary Products
  • Chopperlvya Animal Health
  • Ceva
  • CAHIC
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pet Biopharmaceuticals Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pet Biopharmaceuticals Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pet Biopharmaceuticals Market Dynamics
  1. 2.1 Pet Biopharmaceuticals Industry Trends
  2. 2.2 Pet Biopharmaceuticals Industry Drivers
  3. 2.3 Pet Biopharmaceuticals Industry Opportunities and Challenges
  4. 2.4 Pet Biopharmaceuticals Industry Restraints
3 Pet Biopharmaceuticals Market by Company
  1. 3.1 Global Pet Biopharmaceuticals Company Revenue Ranking in 2025
  2. 3.2 Global Pet Biopharmaceuticals Revenue by Company (2021-2026)
  3. 3.3 Global Pet Biopharmaceuticals Company Ranking (2024-2026)
  4. 3.4 Global Pet Biopharmaceuticals Company Manufacturing Base and Headquarters
  5. 3.5 Global Pet Biopharmaceuticals Company Product Type and Application
  6. 3.6 Global Pet Biopharmaceuticals Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pet Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pet Biopharmaceuticals Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pet Biopharmaceuticals Market by Type
  1. 4.1 Pet Biopharmaceuticals Type Introduction
  2. 4.1.1 Antiparasitic
  3. 4.1.2 Antibacterial
  4. 4.1.3 Biological Products
  5. 4.1.4 Others
  6. 4.2 Global Pet Biopharmaceuticals Sales Value by Type
  7. 4.2.1 Global Pet Biopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Pet Biopharmaceuticals Sales Value by Type (2021-2032)
  9. 4.2.3 Global Pet Biopharmaceuticals Sales Value Share by Type (2021-2032)
5 Pet Biopharmaceuticals Market by Application
  1. 5.1 Pet Biopharmaceuticals Application Introduction
  2. 5.1.1 Prevention
  3. 5.1.2 Treatment
  4. 5.2 Global Pet Biopharmaceuticals Sales Value by Application
  5. 5.2.1 Global Pet Biopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pet Biopharmaceuticals Sales Value by Application (2021-2032)
  7. 5.2.3 Global Pet Biopharmaceuticals Sales Value Share by Application (2021-2032)
6 Pet Biopharmaceuticals Regional Value Analysis
  1. 6.1 Global Pet Biopharmaceuticals Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pet Biopharmaceuticals Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pet Biopharmaceuticals Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pet Biopharmaceuticals Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pet Biopharmaceuticals Sales Value (2021-2032)
  7. 6.3.2 North America Pet Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pet Biopharmaceuticals Sales Value (2021-2032)
  10. 6.4.2 Europe Pet Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pet Biopharmaceuticals Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pet Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pet Biopharmaceuticals Sales Value (2021-2032)
  16. 6.6.2 South America Pet Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pet Biopharmaceuticals Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pet Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
7 Pet Biopharmaceuticals Country-level Value Analysis
  1. 7.1 Global Pet Biopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pet Biopharmaceuticals Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pet Biopharmaceuticals Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pet Biopharmaceuticals Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pet Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pet Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pet Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck Pet Biopharmaceuticals Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Zoetis
  8. 8.2.1 Zoetis Company Information
  9. 8.2.2 Zoetis Business Overview
  10. 8.2.3 Zoetis Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zoetis Pet Biopharmaceuticals Product Portfolio
  12. 8.2.5 Zoetis Recent Developments
  13. 8.3 Virbac
  14. 8.3.1 Virbac Company Information
  15. 8.3.2 Virbac Business Overview
  16. 8.3.3 Virbac Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Virbac Pet Biopharmaceuticals Product Portfolio
  18. 8.3.5 Virbac Recent Developments
  19. 8.4 Vetoquinol
  20. 8.4.1 Vetoquinol Company Information
  21. 8.4.2 Vetoquinol Business Overview
  22. 8.4.3 Vetoquinol Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Vetoquinol Pet Biopharmaceuticals Product Portfolio
  24. 8.4.5 Vetoquinol Recent Developments
  25. 8.5 Ouro Fino Saude
  26. 8.5.1 Ouro Fino Saude Company Information
  27. 8.5.2 Ouro Fino Saude Business Overview
  28. 8.5.3 Ouro Fino Saude Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Ouro Fino Saude Pet Biopharmaceuticals Product Portfolio
  30. 8.5.5 Ouro Fino Saude Recent Developments
  31. 8.6 Norbrook
  32. 8.6.1 Norbrook Company Information
  33. 8.6.2 Norbrook Business Overview
  34. 8.6.3 Norbrook Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Norbrook Pet Biopharmaceuticals Product Portfolio
  36. 8.6.5 Norbrook Recent Developments
  37. 8.7 Jindun
  38. 8.7.1 Jindun Company Information
  39. 8.7.2 Jindun Business Overview
  40. 8.7.3 Jindun Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jindun Pet Biopharmaceuticals Product Portfolio
  42. 8.7.5 Jindun Recent Developments
  43. 8.8 Elanco
  44. 8.8.1 Elanco Company Information
  45. 8.8.2 Elanco Business Overview
  46. 8.8.3 Elanco Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Elanco Pet Biopharmaceuticals Product Portfolio
  48. 8.8.5 Elanco Recent Developments
  49. 8.9 Dechra Veterinary Products
  50. 8.9.1 Dechra Veterinary Products Company Information
  51. 8.9.2 Dechra Veterinary Products Business Overview
  52. 8.9.3 Dechra Veterinary Products Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Dechra Veterinary Products Pet Biopharmaceuticals Product Portfolio
  54. 8.9.5 Dechra Veterinary Products Recent Developments
  55. 8.10 Chopperlvya Animal Health
  56. 8.10.1 Chopperlvya Animal Health Company Information
  57. 8.10.2 Chopperlvya Animal Health Business Overview
  58. 8.10.3 Chopperlvya Animal Health Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Chopperlvya Animal Health Pet Biopharmaceuticals Product Portfolio
  60. 8.10.5 Chopperlvya Animal Health Recent Developments
  61. 8.11 Ceva
  62. 8.11.1 Ceva Company Information
  63. 8.11.2 Ceva Business Overview
  64. 8.11.3 Ceva Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Ceva Pet Biopharmaceuticals Product Portfolio
  66. 8.11.5 Ceva Recent Developments
  67. 8.12 CAHIC
  68. 8.12.1 CAHIC Company Information
  69. 8.12.2 CAHIC Business Overview
  70. 8.12.3 CAHIC Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  71. 8.12.4 CAHIC Pet Biopharmaceuticals Product Portfolio
  72. 8.12.5 CAHIC Recent Developments
  73. 8.13 Boehringer Ingelheim
  74. 8.13.1 Boehringer Ingelheim Company Information
  75. 8.13.2 Boehringer Ingelheim Business Overview
  76. 8.13.3 Boehringer Ingelheim Pet Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Boehringer Ingelheim Pet Biopharmaceuticals Product Portfolio
  78. 8.13.5 Boehringer Ingelheim Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst